Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

Abstract Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer with tumor programmed cell death ligand 1...

Full description

Bibliographic Details
Main Authors: Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
breast cancer
chemotherapy
clinical cancer research
clinical trials
Online Access:https://doi.org/10.1002/cam4.5757

Internet

https://doi.org/10.1002/cam4.5757

Similar Items